Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to Treatment With Teclistamab in Relapsed or Refractory Multiple Myeloma (RRMM)

NCT06352866 is registered in ClinicalTrials.gov with Jack Khouri, MD as lead sponsor.

NCT NCT06352866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06352866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to Treatment With Teclistamab in Relapsed or Refractory Multiple Myeloma (RRMM)
Lead sponsor
Jack Khouri, MD
Phase
Phase 2
Overall status
Withdrawn
Start date
January 1, 2025
Completion date
December 1, 2025
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cytokine release syndrome, immune effector cell associated neurotoxicity syndrome, multiple myeloma, refractory multiple myeloma